Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.58 |
| ▸ | MMP9 | P14780 | 2/20 | 0.58 |
| ▸ | PLAU | P00749 | 5/20 | 0.48 |
| ▸ | HPN | P05981 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649246 | 1.00 | MMP2 (0.58) | MMP2MMP9PLAUHPNTDP1 | |
| Hydrochloric Acid SCHEMBL9122752 | 0.99 | MMP2 (0.57) | MMP2MMP9PLAUHPNTDP1 | |
| Formaldehyde SCHEMBL19520520 | 0.87 | MMP2 (0.56) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL6893970 | 0.87 | MMP2 (0.61) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL8001084 | 0.87 | MMP9 (0.76) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL10585071 | 0.87 | MMP9 (0.76) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL457772 | 0.87 | MMP9 (0.76) | MMP2MMP9PLAUHPNTDP1 | |
| Formaldehyde SCHEMBL21493269 | 0.86 | MMP2 (0.55) | MMP2MMP9PLAUHPNTDP1 | |
| Hydrochloric Acid SCHEMBL9087107 | 0.86 | MMP9 (0.74) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL28509074 | 0.86 | MMP2 (0.60) | MMP2MMP9PLAUHPNTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240361469-A1 | SERVICES AND APPLICATIONS FOR A COMMUNICATIONS NETWORK | MOBILE MAVEN LLC | 2024-10-31 | — | — | US | claimed |
| US-20260149760-A1 | SYSTEMS AND METHODS FOR MANAGING SOFTWARE SERVICES | SAP SE (DE) | 2026-05-28 | — | — | US | disclosed |
| US-20260140888-A1 | CACHE EVICTION IN A MULTI-TENANT ARCHITECTURE | SAP SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12608244-B2 | Resource utilization in job scheduler systems | SAP SE (DE) | 2026-04-21 | — | — | US | disclosed |
| US-12438825-B2 | Parameterized quality of service in a network | ENTROPIC COMMUNICATIONS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12423489-B2 | Modifying a finite element mesh | SIEMENS INDUSTRY SOFTWARE NV (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250156246-A1 | RESOURCE UTILIZATION IN JOB SCHEDULER SYSTEMS | SAP SE (DE) | 2025-05-15 | — | — | US | disclosed |
| WO-2025098951-A1 | ACTIVATING A PSCELL | NOKIA TECHNOLOGIES OY (FI) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025043252-A1 | COMPARATIVE EXERCISE SESSION EQUIVALENCE, DIFFERENTIAL AIR PRESSURE (DAP) SYSTEM, EQUIVALENCE ENGINE AND RELATED METHODS AND DEVICES | WHALEN SEAN (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-4479805-A1 | SYSTEMS AND METHODS FOR ASSESSING AND CONTROLLING SUSTAINABILITY OF AN ENERGY PLANT | Tyco Fire & Security GmbH (CH) | 2024-12-25 | — | — | EP | disclosed |
| US-20220067242-A1 | MODIFYING A FINITE ELEMENT MESH | SIEMENS INDUSTRY SOFTWARE LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| EP-3961471-A1 | MODIFYING A FINITE ELEMENT MESH | Siemens Industry Software NV (BE) | 2022-03-02 | — | — | EP | disclosed |
| CN-114119914-A | Modifying a finite element mesh | 西门子工业软件公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20080312212-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1966165-A1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKER | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071400-A1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKER | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-0367302-A2 | Process for semi-synthesis of human insulin, water-soluble cross-linked Achromobacter protease I for use therein and a process for preparing the same | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4581332-A | HYDROLYSES LYSINE ESTER OR AMIDE BONDS DERIVED FROM THE CARBOXY GROUP | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1986-04-08 | — | — | US | disclosed |
| EP-0094095-A2 | Bicyclic carboxylic acids and their alkyl and aralkyl esters | F. HOFFMANN-LA ROCHE AG (CH) | 1983-11-16 | — | — | EP | disclosed |
| EP-0092829-A2 | Process for semi-synthesis of human insulin and alkaline protease for use therein | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260140888-A1 | CACHE EVICTION IN A MULTI-TENANT ARCHITECTURE | SMN1; SMN2, SET, THOC2 | MMP2 4496/4885MMP9 3845/4885PLAU 643/4885 |
| US-12608244-B2 | Resource utilization in job scheduler systems | SET, TERF2, RIF1 | MMP2 1588/4885MMP9 3259/4885PLAU 406/4885 |
| US-20080312212-A1 | Organic Compounds | TRPA1, TRPV1, TRPV3 | MMP2 2368/4885MMP9 1584/4885PLAU 3355/4885 |
| US-20260149760-A1 | SYSTEMS AND METHODS FOR MANAGING SOFTWARE SERVICES | MRPS2, SAAL1, QARS1 | MMP2 2196/4885MMP9 3487/4885PLAU 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.